HMGCR and neoplasm: Consistently, immunohistochemical staining of tumor tissues revealed markedly higher expression of p-FAK, p-AKT, and HMGCR proteins in the sorafenib monotherapy group, which was significantly inhibited in the combination group (Fig. 8G).